Szisztémás szklerózis (szkleroderma): vizsgálatok itt: Lengyelország
11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Ossy, Warsaw
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisNot yet taking people in LengyelországRollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
- Where
- Bydgoszcz, Cracow, Katowice, Kielce, Ozarowice, Warsaw
- People
- 340 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-526419-13-00 - 2. fázisTaking peopleEvaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Where
- Bydgoszcz, Nowa Sol, Warszawa
- Életkor
- 18 év and over
- People
- 36 worldwide
- Run by
- Mediar Therapeutics Inc.
See details and how to join2025-523288-39-00 - 3. fázisTaking peopleA Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Where
- Bialystok, Bydgoszcz, Cracow, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 448 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00 - 1. fázisNot yet taking people in LengyelországA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Bydgoszcz, Krakow, Poznan
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - 2. fázisTaking peopleEncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Where
- Bydgoszcz, Nowa Sól, Warsaw
- Életkor
- 18 év and over
- People
- 85 worldwide
- Run by
- Mediar Therapeutics
See details and how to joinNCT07287670 - 2. fázisTaking peoplePlatform Clinical Study for Conquering Scleroderma
- Where
- Bydgoszcz, Gdansk, Katowice, Poznan, Szczecin, Warsaw
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Scleroderma Research Foundation, Inc.
See details and how to joinNCT06195072 · EU 2023-507129-40-00 - 2. fázisTaking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Bydgoszcz, Lodz, Warsaw
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - 1. fázisTaking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Bytom, Gdansk, Gliwice, Lodz
- Életkor
- 18 év and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00 - 3. fázisTaking peopleStudy of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
- Where
- Warsaw
- Életkor
- 18 év to 74 év
- People
- 86
- Run by
- National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
See details and how to joinNCT06297096 - 2. fázisTaking peopleA Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Where
- Bialystok, Cracow, Malbork, Nowa Sol, Warsaw
- Életkor
- 18 év and over
- People
- 162 worldwide
- Run by
- Galderma R&D
See details and how to joinNCT07047690 · EU 2025-522294-11-00